A single-center, retrospective cohort study was conducted to assess response to treatment and progression of disease in patients with severe lymphopenia undergoing treatment with immune checkpoint inhibitors for NSCLC.
Canakinumab is a human monoclonal antibody that binds with high affinity and selectivity to interleukin-1beta.
The U.S. Preventive Services Task Force recommends annual LDCT screening for lung cancer for high-risk adults aged 50 to 80 years.
Lorbrena is a third generation ALK tyrosine kinase inhibitor.
A team of international investigators deployed a survey to understand the needs of patients with EGFR-positive lung cancer community.
Although patient-reported outcomes measures were similar with lorlatinib and crizotinib in non-small cell lung cancer, more patients reported improvement in symptoms with lorlatinib.
The addition of durvalumab after chemoradiotherapy for treatment of stage III NSCLC was cost-effective compared with chemoradiotherapy alone.
Continued approval of the indication was contingent upon establishing the superiority of Keytruda as determined by overall survival.
The approval was based on data from 3 randomized, placebo-controlled trials that included 245 adults with ES-SCLC.
Study data presented at the 2020 World Conference on Lung Cancer in Singapore illustrate the utility of a 10-marker methylation panel in lung cancer.
